The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) [9]

Blood

Volumn 108, Issue 5, 2006, Pages 1781-1782

  Boissinot, Marjorie ^b   Garand, Richard ^b   Hamidou, Mohamed ^b   Hermouet, Sylvie ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

BONE MARROW BIOPSY; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LETTER; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WORLD HEALTH ORGANIZATION;

EID: 33748177825     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-008227     Document Type: Letter

References (8)

1. Brunning RD, Bennett JM, Flandrin G, Matutes E. Refractory anaemia with ring sideroblasts. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours: Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001:69.
2. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM. Essential thrombocythemia with ringed sideroblasts: a heterogenous spectrum of diseases, but not a distinct entity. Haematologica. 2002;87:392-399.
3. Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol. 2005;131:180-184.
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
5. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
6. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. Prepublished on May 25, 2006, as DOI 10.1182/blood-2006-01-013540.
7. Ohyashiki K, Aota Y, Akahane D, et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia. 2005;19:2359-2360.
8. Dobo I, Boiret N, Lippert E, et al. A standardized endogenous megakaryocytic/erythroid (EMC/EEC) colony assay for the diagnosis of essential thrombocythemia. Haematologica. 2004;89:1203-1208.